Whn ft bl t b trnrtd t b ud nd burnd fr ful t rvd nrg, t nt bng trd ft ll
Contact us at [email protected] to explore how we can collaborate
The breadth of the DXd platform patent estate means that any biosimilar manufacturer seeking to develop a Dato-DXd follow-on must navigate both the TROP2 antibody IP and the linker-payload platform IP, creating a two-layer patent challenge
For example, a 2025 study in the Journal of the American Medical Association (JAMA) found people taking Ozempic were about 1.8 times as likely to experience vision loss from NAION, than those prescribed other diabetes medications
(18) The study further revealed that the effects of liraglutide on osteoblast differentiation and mitochondrial function were mediated through the GLP-1 receptor (GLP1R), as blocking GLP1R or AMP-activated protein kinase (AMPK) inhibited these outcomes
These legal battles often focus on the manufacturers' obligations to provide transparent risk assessments to both doctors and patients
